Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2693-2699

  Inagaki, Hiroaki ^a   Tsuruoka, Hiroyuki ^a   Hornsby, Michael ^b   Lesley, Scott A ^b   Spraggon, Glen ^b   Ellman, Jonathan A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 ARYLPHENOXY)ACETALDEHYDE INHIBITOR; CATHEPSIN S; CATHEPSIN S INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; MOLECULAR WEIGHT; SYNTHESIS; X RAY;

ACETALDEHYDE; BIPHENYL COMPOUNDS; CATHEPSINS; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34250219213     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070111+     Document Type: Article

References (18)

1. Wood, W. J. L.; Patterson, A. W.; Tsuruoka, H.; Jain, R. K.; Ellman, J. A. Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 2005, 127, 15521-15527.
2. Salisbury, C. M.; Ellman, J. A. Rapid identification of potent nonpeptidic serine protease inhibitors. ChemBioChem 2006, 7, 1034-1037.
3. (a) Leroy, V.; Thurairatnam, S. Cathepsin S inhibitors. Expert Opin. Ther. Pat. 2004, 14, 301-311.
4. (b) Yasuda, Y.; Kaleta, J.; Broemme, D. The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics. Adv. Drug Delivery Rev. 2005, 57, 973-993.
5. (c) Leung Toung, R.; Zhao, Y.; Li, W.; Tam, T. F.; Karimian, K.; Spino, M. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem. 2006, 13, 547-581.
6. Patterson, A. W.; Wood, W. J. L.; Hornsby, M.; Lesley, S.; Spraggon, G.; Ellman, J. A. Identification of selective, nonpeptidic nitrile inhibitors of camepsin S using the substrate activity screening method. J. Med. Chem. 2006, 49, 6298-6307.
7. Reiffenrath, V.; Krause, J. Process for the Preparation of 2,3-Difluorobenzenes. German Patent Application DE 88-3807910 19880310, 1988.
8. Dantlgraber, G.; Shen, D.; Diele, S.; Tschierske, C. Antiferroelectric switchable mesophases of nonchiral bent-core liquid crystals containing fluorinated central cores. Chem. Mater. 2002, 14, 1149-1158.
9. Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Proteases universally recognize beta strands in their active sites. Chem. Rev. 2005, 105, 973-1000.
10. Palmer, J. T.; Hirschbein, B. L.; Cheung, H.; McCarter, J.; Janc, J. W.; Yu, Z. W.; Wesolowskib, G. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2909-2914.
11. Liu, H.; Tully, D. C.; Epple, R.; Bursulaya, B.; Li, J.; Harris, J. L.; Williams, J. A.; Russo, R.; Tumanut, C.; Roberts, M. J.; Alper, P. B.; He, Y.; Karanewsky, D. S. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. Bioorg. Med. Chem. Lett. 2005, 15, 4979-4984.
12. Tully, D. C.: Liu, H.; Chatterjee, A. K.; Alper, P. B.; Epple, R.; Williams, J. A.; Roberts, M. J.; Woodmansee, D. H.; Masick, B. T.; Tumanut, C.; Li, J.; Spraggon, G.; Hornsby, M.; Chang, J.; Tuntland, T.; Hollenbeck, T.; Gordon, P.; Harris, J. L.; Karanewsky, D. S. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. Bioorg. Med. Chem. Lett. 2006, 16, 5112-5117.
13. Maly, D. J.; Leonetti, F.; Backes, B. J.; Dauber, D. S.; Harris, J. L.; Craik, C. S.; Ellman, J. A. Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J. Org. Chem. 2002, 67, 910-915.
14. Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M.; Hanada, K. L-trans-Epoxysuccinyl-leucylamido(4-guanidino) butane (E-64) and its analogs as inhibitors of cysteine proteinases including cathepsins B, H, and L. Biochem. J. 1982, 201, 189-198.
15. Cha, S.; Agarwal, R. P.; Parks, J. Tight-binding inhibitors-II: non-steady state nature of inhibition of mild xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem. Pharmacol. 1975, 24, 2187-2197.
16. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
17. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.
18. Collaborative computing project, number 4. The CCP4 suite: Programs for protein crystallography, version 3.1. Acta Crystallogr. 1994, D50, 760-763.